By vgreene, 10 October, 2020 See <a href=https://clinicaltrials.gov/ct2/results?cond=&term=covid+fostamatinib&cntry=US&state=&city=&dist=&Search=Search><b><u>U.S. fostamatinib trials</u></b></a>
By vgreene, 10 October, 2020 Compassionate Use of JAK1/2 Inhibitor Ruxolitinib for Severe COVID-19: A Prospective Observational Study; <a href=https://www.nature.com/articles/s41375-020-01018-y><b><u>access full-text <i>Leukemia</i> article</u></b></a>
By vgreene, 10 October, 2020 Risk of COVID-19-Related Death Among Patients With Chronic Obstructive Pulmonary Disease or Asthma Prescribed Inhaled Corticosteroids: An Observational Cohort Study Using the OpenSAFELY Platform; <a href=https://www.thelancet.com/journals/lanres/article/P
By vgreene, 10 October, 2020 A Prospective, Randomized, Open-Label Trial of Early Versus Late Favipiravir in Hospitalized Patients With COVID-19; <a href= https://aac.asm.org/content/early/2020/09/16/AAC.01897-20 ><b><u>access <i>Antimicrob Agents Chemother</i> article</u></b></a>
By vgreene, 10 October, 2020 Arbidol Monotherapy Is Superior to Lopinavir/Ritonavir in Treating COVID-19; <a href=https://www.journalofinfection.com/article/S0163-4453(20)30188-2/fulltext><b><u>access <i>J Infect</i> article</u></b></a>
By vgreene, 10 October, 2020 <a href=https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32013-4/fulltext><b><u>Access full-text <i>Lancet</i> article</u></b></a>
By vgreene, 10 October, 2020 <b>Study considerations:</b> randomized but open-label; unclear if adequate dose used; limited number of intubated pts; no collection of virological or laboratory parameters
By vgreene, 10 October, 2020 No significant difference in 28-day all-cause mortality (RR 1.03, 95% CI 0.91 to 1.17), incl across subgroups; no significant difference in time to discharge or proportion of pts discharged
By vgreene, 10 October, 2020 Hospitalized pts (mean age 66.2y) w/ suspected or confirmed COVID-19 randomized to LPV/r 400 mg/100 mg bid plus SOC for up to 10 days (n=1616) vs SOC only (n=3424); 25% pts w/ no ventilatory support, most pts needed O<sub>2</sub> only, small proportion ne
By vgreene, 10 October, 2020 Randomized, controlled, open-label, adaptive platform study; current analysis incl LPV/r vs SOC only, results for other tx arms published or forthcoming
